A flu variant is causing a nationwide surge in cases, and health experts are concerned about the impact of holiday travel and gatherings. This new strain, known as subclade K, has already caused early outbreaks in several countries and is now spreading rapidly across the US.
The US Centers for Disease Control and Prevention (CDC) reports that over half of the states are experiencing high to very high levels of flu-related illnesses. As of December 20th, the CDC estimates a staggering 7.5 million cases, 81,000 hospitalizations, and 3,100 deaths, including at least eight pediatric deaths. These numbers are expected to rise further due to holiday-related activities.
Some states are witnessing record-breaking case numbers. New York State, for instance, recorded 71,000 cases in a single week ending December 20th, the highest weekly total since 2004. Despite this surge, experts are cautious about predicting the severity of this flu season compared to last winter's.
But here's where it gets controversial... Subclade K is a mutated form of the H3N2 strain, a Type A flu subtype. While it's not a completely new virus, its mutations allow it to partially evade immunity from this year's vaccine, according to virology expert Andrew Pekosz.
So, will the current flu vaccine help? Health experts encourage vaccination, emphasizing that it's not too late. Although the vaccine may not be a perfect match for subclade K, early data from the UK suggests it still provides partial protection, especially against severe illness and hospitalization. The vaccine remains effective against other circulating strains, including H1N1 and Type B influenza.
Currently, only about 42% of Americans have received a flu vaccine this year, according to CDC data.
Who is most at risk? Flu poses the greatest danger to adults aged 65 and older, pregnant women, young children, and individuals with chronic conditions like asthma, diabetes, heart disease, or weakened immune systems. The CDC recommends annual flu vaccination for everyone aged six months and older.
In addition to vaccines, prescription antiviral medications can reduce flu severity, especially for high-risk patients, but they must be started within one to two days of symptom onset.
Vaccination options are expanding, with flu vaccines available as injections for all age groups and the FluMist nasal spray for people aged 2 to 49. This season, some individuals may be eligible to self-administer FluMist at home, increasing access as flu activity intensifies across the nation.
